Bio Path Holdings EV/EBIT

Que fait Bio Path Holdings ? Bio-Path Holdings, Inc. develops therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) using its DNAbilize technology platform. The company's drug delivery system, DNAbilize, utilizes P-ethoxy, a DNA backbone modification that protects antisense drugs from enzymatic destruction in the body. This platform enables systemic distribution of antisense drug substances to target over-expressed proteins in blood diseases and solid organs. Bio-Path has three antisense drug candidates in development targeting over five different cancer disease indications. The company's primary revenue stream comes from the development and commercialization of its antisense drug candidates. These therapies are designed to treat specific blood cancers and solid organ diseases where proteins are over-expressed. Bio-Path's technology allows for targeted protein inhibition without systemic toxicity, making it suitable for treating multiple cancer indications. The company focuses on developing therapies for AML and CML, which are serious blood disorders requiring specialized treatment approaches. Bio-Path Holdings, Inc. is a biotechnology company headquartered in Bellaire, Texas, with 10 full-time employees. It utilizes its DNAbilize platform to create antisense drug candidates that target over-expressed proteins in various diseases. The company's technology enables systemic delivery of antisense therapies across the body, allowing for reduction or elimination of disease-causing proteins. This approach is intended to provide targeted treatment for multiple cancer indications including AML and CML. Bio Path Holdings est l'une des entreprises les plus populaires sur Eulerpool.